FDA CRL Delays ViiV’s Long-Acting Cabotegravir Regimen
Manufacturing Questions Triggered FDA Complete Response Letter
ViiV Healthcare will not be able to launch its cabotegravir and rilpivirine long-acting HIV treatment in January after receiving an FDA Complete Response Letter.
